GH Research Plc
(NASDAQ : GHRS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
MRKMerck & Co., Inc. 1.76%80.890.7%$1590.63m
JNJJohnson & Johnson 0.04%163.940.7%$1030.66m
PFEPfizer Inc. 1.75%42.830.9%$940.36m
ABBVAbbVie, Inc. 1.01%108.541.9%$680.40m
BMYBristol-Myers Squibb Co. 1.10%58.221.0%$660.43m
LLYEli Lilly & Co. 0.63%243.831.1%$610.89m
AZNAstraZeneca Plc 0.91%60.711.0%$367.32m
NVSNovartis AG 1.74%84.600.2%$177.09m
GSKGlaxoSmithKline Plc 0.80%39.490.2%$162.09m
RGENRepligen Corp. 2.21%268.466.8%$118.18m
AVIRAtea Pharmaceuticals, Inc. -3.33%13.360.3%$117.82m
VTRSViatris, Inc. 3.01%13.980.0%$92.74m
NVONovo Nordisk A/S -0.08%104.570.1%$91.62m
EDSAEdesa Biotech, Inc. -0.24%8.200.0%$73.91m
SNYSanofi 2.67%49.340.2%$65.14m

Company Profile

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. It develops therapeutic products for the patients who are suffering from Treatment Resistant Depression (TRD). The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Sch├â┬Ânharting and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.